A61K 39/0275
Salmonella
Official title: {Salmonella}
A61K39/0275 (Salmonella) appears on 369 US grants and 457 published applications in this corpus.
Search patents in A61K- Granted patents
- 369
- Published applications
- 457
- Assignees
- 248
- Inventors
- 745
- Latest grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1979 | 1 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 2 | 0 |
| 1986 | 2 | 0 |
| 1987 | 1 | 0 |
| 1988 | 4 | 0 |
| 1989 | 2 | 0 |
| 1990 | 1 | 0 |
| 1991 | 2 | 0 |
| 1992 | 2 | 0 |
| 1993 | 5 | 0 |
| 1994 | 4 | 0 |
| 1995 | 5 | 0 |
| 1996 | 3 | 0 |
| 1997 | 8 | 0 |
| 1998 | 12 | 0 |
| 1999 | 8 | 0 |
| 2000 | 6 | 0 |
| 2001 | 2 | 1 |
| 2002 | 7 | 14 |
| 2003 | 4 | 11 |
| 2004 | 7 | 18 |
| 2005 | 12 | 8 |
| 2006 | 12 | 8 |
| 2007 | 6 | 15 |
| 2008 | 5 | 15 |
| 2009 | 3 | 14 |
| 2010 | 3 | 16 |
| 2011 | 13 | 30 |
| 2012 | 11 | 16 |
| 2013 | 14 | 15 |
| 2014 | 17 | 22 |
| 2015 | 20 | 23 |
| 2016 | 21 | 26 |
| 2017 | 13 | 28 |
| 2018 | 20 | 23 |
| 2019 | 21 | 17 |
| 2020 | 24 | 25 |
| 2021 | 15 | 22 |
| 2022 | 11 | 23 |
| 2023 | 13 | 19 |
| 2024 | 9 | 22 |
| 2025 | 11 | 13 |
| 2026 | 5 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Live attenuated non-transmissible vaccines7 Jul 2026US 12,674,131 B2University of Maryland, Baltimore
- Gut bacteria derived microvesicles for vaccine delivery16 Jun 2026US 12,653,877 B2Quadram Institute Bioscience
- Compositions and methods of treatment comprising tumor-targeting bacteria and chemotherapy or immunotherapy agent9 Jun 2026US 12,648,970 B2The Curators of the University of Missouri
- Live self-destructing bacterial adjuvants to enhance induction of immunity19 May 2026US 12,629,417 B2University of Florida Research Foundation, Inc.
- Dosage and administration of a bacterial saccharide glycoconjugate vaccine27 Jan 2026US 12,533,418 B2Glaxosmithkline Biologicals SA
- Development of carbohydrate-based anti-salmonella vaccines8 Oct 2026US 2026/0306602 A1Board of Trustees of Michigan State University
- A broadly protective prophylactic vaccine against pseudomonas aeruginosa24 Sep 2026US 2026/0284172 A1University of Kansas
- Oral vaccine20 Aug 2026US 2026/0240985 A1WestfäLische Wilhelms-UniversitäT MüNster
- Respiratory dry powder delivery13 Aug 2026US 2026/0232581 A1Board of Regents, The University of Texas System
- Tumor-targeting pharmaceutical combinations30 Jul 2026US 2026/0216257 A1Baccine Ltd.
Most cited
By later US patents
- Avirulent microbes and uses therefor: Salmonella typhi109US 5,387,744 AWashington University · 1995
- Avirulent microbes and uses therefor: salmonella typhi103US 5,294,441 AWashington University · 1994
- Avirulent microbes and uses therefor102US 5,389,368 AWashington University · 1995
- Vaccines containing avirulent phop-type microorganisms101US 5,424,065 AWashington University · 1995
- Novel non-reverting shigella live vaccines87US 5,077,044 AThe Board of Trustees of the Leland Stanford Jr. University · 1991